Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.

@article{Fitzgerald1996PrevalenceOG,
  title={Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.},
  author={Michael Fitzgerald and D. Paul Harkin and Sandra Silva-Arrieta and Deborah J Macdonald and L C Lucchina and Hilal Unsal and Elena O'Neill and J Koh and Dianne M. Finkelstein and Kurt J Isselbacher and Arthur J. Sober and Daniel A. Haber},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={1996},
  volume={93 16},
  pages={8541-5}
}
Five to ten percent of individuals with melanoma have another affected family member, suggesting familial predisposition. Germ-line mutations in the cyclin-dependent kinase (CDK) inhibitor p16 have been reported in a subset of melanoma pedigrees, but their prevalence is unknown in more common cases of familial melanoma that do not involve large families with multiple affected members. We screened for germ-line mutations in p16 and in two other candidate melanoma genes, p19ARF and CDK4, in 33… CONTINUE READING